RespireRx Pharmaceuticals Inc (fka RSPI)

[rusbrn]

I am sure someone will give you a more complete answer but I will try. If SGP were to bring to market either of their compounds in Skizo. or Depression they would owe double digit royalty to Cortex going as high as 18%. If they should bring them to market in the US for ADHD they would have to make a deal with Cortex, In Europe there is still some ambiguity about the patent status.
It seems likely they would want one of Cortex's new molecules for any new drug to market because of the extended patent life.
I know you will get a more complete rundown from others and I will read it too.